Front. Nutr.Frontiers in NutritionFront. Nutr.2296-861XFrontiers Media S.A.10.3389/fnut.2024.1470833NutritionOriginal ResearchThe impact of Composite Dietary Antioxidant Index on the relationship between eczema and depression symptoms in US adultsZhangTian†ZhangRuohua†SongTingChenFang*WeiYuegang*Department of Dermatology, Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine, Nanjing, China
Edited by: Rixiang Xu, Anhui Medical University, China
Reviewed by: Qida He, City University of Hong Kong, Hong Kong SAR, China
Amara Rasheed, Government College University Faisalabad, Pakistan
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Aims
The study aims to explore the associations of eczema, Composite Dietary Antioxidant Index (CDAI), with depression symptoms in adults based on the National Health and Nutrition Examination Surveys (NHANES) database.
Methods
In total, 3,402 participant data were extracted from the NHANES 2005–2006. The relationship between eczema, CDAI, and depression symptoms was explored by utilizing weighted univariate and multivariate logistic regression models, presenting as odds ratios (ORs) and 95% confidence intervals (CIs). The additive interaction between eczema, CDAI, and depression symptoms was measured by relative excess risk due to interaction (RERI) and the attributable proportion of interaction (AP). Subsequently, the associations of eczema, CDAI, with depression were also explored in different gender, body mass index (BMI), and smoking subgroups.
Results
Of the 3,402 participants included, the mean age was 46.76 (0.83) years old, and 174 (5.11%) participants had depression symptoms. In the adjusted model, both eczema (OR = 3.60, 95%CI: 2.39–5.40) and CDAI (OR = 1.97, 95%CI: 1.19–3.27) were associated with a higher prevalence of depression symptoms. Compared to the participants with high CDAI and no eczema, those participants with low CDAI (eczema: OR = 7.30, 95%CI: 4.73–11.26; non-eczema: OR = 1.84, 95%CI: 1.06–3.19) have higher odds of depression symptoms, no matter have eczema or not. When under low CDAI levels, eczema was associated with increased odds of depression symptoms (OR = 3.76, 95%CI: 2.34–6.03). When under low CDAI level, eczema was also related to elevated odds of depression symptoms in those males, females, BMI <25, BMI ≥25, non-smoking, and smoking.
Conclusion
CDAI could modulate the association of eczema with depression symptoms in adults.
Eczema, or atopic dermatitis, is a chronic inflammatory skin condition characterized by pruritus, recurrent eczematous patches, and plaques (1). Typically manifesting in early childhood, it may persist into adulthood or even emerge later in life (1). In the United States (U.S), approximately 10–20% of adults experience eczema at some point (2, 3). Beyond the physical discomfort it causes, eczema profoundly impacts mental health (4). Adults with eczema are at an elevated risk of developing psychiatric disorders, including depression, anxiety, and sleep disturbances (5, 6). The burden of eczema transcends its dermatological symptoms, resulting a significant reduction in quality of life and increased healthcare utilization due to both physical discomfort and associated psychological distress (4).
Depression, a common comorbidity of eczema, further exacerbates the considerable burden of the condition (7). Individuals with eczema are at a heightened risk of experiencing depression compared to those without the disorder (8). The mechanisms underlying this association are complex and may involve chronic stress due to the physical symptoms of eczema, social stigma, sleep disturbances, and the psychological impact of living with a visible chronic condition (8–10). Understanding the relationship between eczema and depression is essential for developing effective interventions that address both the dermatological and psychological aspects of the disease.
Oxidative stress is a pivotal pathophysiological mechanism implicated in both eczema and depression (11, 12). The Composite Dietary Antioxidant Index (CDAI) is a comprehensive measure of dietary antioxidant intake, encompassing a broad spectrum of antioxidants, including vitamins C and E, carotenoids, and flavonoids (13). Research indicates that CDAI was inversely associated with depression in the general population (14). Additionally, dietary antioxidant intake has shown a negative correlation with childhood eczema (15). Given these associations, CDAI may serve as a potential moderator influencing the relationship between eczema and depression. Hence, this study aims to investigate the moderating effect of CDAI on the association between eczema and depression symptoms in adults.
MethodsStudy design and participants
The National Health and Nutrition Examination Surveys (NHANES), a major program by the National Center for Health Statistics (NCHS), assesses the nutrition and health status of both adults and children in the U.S. The NHANES protocol has received approval from the NCHS Research Ethics Review Board, with all participants providing informed consent before the survey. The ethical approval was granted with an exemption from the Jiangsu Province Hospital of Chinese Medicine.
Data for participants were extracted from the NHANES 2005–2006 cycle, the only period with complete questionnaires on eczema. The participants included individuals aged ≥20 years old, who having an assessment for eczema and depression symptoms, as well as dietary intake data. Exclusion criteria comprised: (1) individuals taking antidepressants, (2) extreme caloric intake (defined as <600 kcal or > 4,200 kcal per day for men, and < 500 kcal or > 3,600 kcal per day for women) (16), and (3) missing data on important covariates.
Determination of eczema
Eczema diagnosis was based on self-reported data from the NHANES questionnaire, where individuals indicated a positive response to the query, “Has a doctor or other health professional ever told you that you have eczema” (17).
CDAI assessment
CDAI was calculated using six dietary antioxidant micronutrients: vitamins A, C, E, zinc, magnesium, and selenium, following Wright’s method (17). Each nutrient was standardized by subtracting the mean and dividing by the standard deviation to estimate CDAI. Standardized intakes were then summarized with equal weighting to derive the composite CDAI. In our study, the CDAI score was categorized into two levels based on the median.
Depression assessment
Depression symptoms were defined using the Patient Health Questionnaire (PHQ-9), a 9-item screening tool assessing the frequency of depressive symptoms over the past 2 weeks via face-to-face mobile examination center interview (18). Respondents rated symptoms such as anhedonia, depressed mood, sleep disturbance, fatigue, appetite changes, low self-esteem, concentration problems, psychomotor disturbances, and suicidal ideation on a 0–3 scale. The PHQ-9 total score ranges from 0 to 27 points, with a score ≥ 10 indicating clinically relevant depressive symptoms (19).
Covariates
The covariates in this study included race, poverty income ratio (PIR), marriage, education level, sleep duration, smoking, house smoker, hypertension, diabetes, cardiovascular disease (CVD), and serum vitamin D. Smoking status was determined according to the question “Have you smoked at least 100 cigarettes in your entire life.” Hypertension, as measured by NHANES, was self-reported, applying antihypertensive drugs and blood pressure measurements consistent with previous studies (20, 21). Self-reported hypertension was assessed by participants having a positive answer to the question “Have you ever been told by a doctor or other health professional that you had hypertension, also called high blood pressure.” Hypertension, measured by the NHANES, was defined as a mean systolic blood pressure ≥ 130 mmHg or diastolic blood pressure or ≥ 80 mmHg, based on four measurements (22). Participants who were diagnosed with diabetes were defined as follows: (1) fasting blood glucose ≥7 mmol/L, (2) Hemoglobin A1c ≥6.5%, (3) self-reported diabetes which was diagnosed by professional physicians before, (4) taking insulin or other hypoglycemic drugs (23, 24). The medical conditions section, identified by the variable name prefix MCQ, includes self-and proxy-reported interview data on a wide range of health conditions and medical history for children and adults. Questions “Has a doctor or other health professional ever informed you that you had congestive heart failure, coronary heart disease, angina, heart attack, stroke, etc.?” (labeled MCQ 160 B-F in household questionnaires administered during home interviews) were utilized to identify participants with a history of CVD if they answered “yes” to any of these questions.
Statistical analysis
Considering the recommendations of NHNAES, appropriate sample weights (SDMVPSU, SDMVSTRA, WTMEC2YR) were applied for all analyses. Continuous variables were expressed as means and standard error (S.E), and weight t-tests were utilized for comparisons between the depression and non-depression groups. The constitutional ratio was provided for categorical variables, and Chi-square tests were employed for comparisons between the two groups. Potential covariates were selected according to the weighted logistic regression models, with detailed results of covariates selection presented in Supplementary Table S1. Weighted multivariable logistic regression models were employed to investigate the associations of eczema, CDAI, with depression symptoms, with results reported as 95% confidence intervals (CIs) and odds ratios (ORs). In addition, the additive interaction between eczema, CDAI, and depression symptoms was measured by relative excess risk due to interaction (RERI) and the attributable proportion of interaction (AP). When the confidence interval of RERI and AP contained 0, there was no additive interaction. Subsequently, the associations of eczema, CDAI, with depression were also explored in different gender, body mass index (BMI), and smoking subgroups. All analyses were conducted using R version 4.2.3 (2023-03-15 ucrt), with a significance threshold of p < 0.05.
ResultsCharacteristics of participants
In total, 3,402 participants were included in the current study (Figure 1). The basic characteristics based on depression were presented in Table 1. Of those participants, the mean age was 46.76 (0.83) years old, and 50.92% were female. And 174 (5.11%) individuals have depression symptoms Statistical differences were found between depression and non-depression groups in PIR, marriage, education level, physical activity, sleep duration, smoking, house smoker, hypertension, diabetes, CVD, serum vitamin D, eczema, CDAI, and six components of CDAI (all p < 0.05).
Flowing chart of the selection process.
Characteristics of the participants.
Variables
Total (n = 3,402)
Depression
P
No (n = 3,228)
Yes (n = 174)
Age, years, mean (±S.E)
46.76 (±0.83)
46.81 (±0.82)
45.70 (±2.10)
0.565 a
Gender, n (%)
0.574 b
Female
1752 (50.92)
1,654 (50.82)
98 (52.97)
Male
1,650 (49.08)
1,574 (49.18)
76 (47.03)
Race, n (%)
0.126 b
Non-Hispanic White
1710 (72.45)
1,638 (72.79)
72 (65.00)
Non-Hispanic Black
762 (11.06)
707 (10.73)
55 (18.32)
Mexican American
697 (8.03)
659 (7.97)
38 (9.37)
Other Race
233 (8.46)
224 (8.51)
9 (7.32)
PIR, n (%)
<0.001 b
<1.85
1,219 (24.57)
1,119 (23.49)
100 (48.29)
≥1.85
2076 (72.90)
2004 (73.89)
72 (51.30)
Unknown
107 (2.53)
105 (2.62)
2 (0.42)
Marriage, n (%)
<0.001 b
Married/Living with partner
2,211 (67.63)
2,118 (68.28)
93 (53.24)
Single/Separated/Divorced/Widowed
1,191 (32.37)
1,110 (31.72)
81 (46.76)
Education, n (%)
<0.001 b
Below high school
904 (16.60)
834 (16.12)
70 (27.10)
High school/GED or Equivale
802 (24.43)
749 (23.88)
53 (36.52)
Above high school
1,696 (58.97)
1,645 (60.00)
51 (36.39)
Height, cm, mean (±S.E)
169.03 (±0.24)
169.07 (±0.24)
168.30 (±0.85)
0.374 a
Weight, kg, mean (±S.E)
81.70 (±0.84)
81.60 (±0.83)
84.04 (±2.65)
0.337 a
BMI, kg/m2, n (%)
0.919 b
<25
1,024 (33.15)
973 (33.13)
51 (33.66)
≥25
2,378 (66.85)
2,255 (66.87)
123 (66.34)
PA, MET·min/week, n (%)
<0.001 b
<450
670 (20.49)
645 (20.69)
25 (16.07)
≥450
1,433 (47.34)
1,396 (48.36)
37 (24.92)
Unknown
1,299 (32.17)
1,187 (30.95)
112 (59.01)
Sleep duration, hours, n (%)
<0.001 b
7–9
2054 (62.80)
1990 (63.85)
64 (39.74)
<7
1,264 (35.24)
1,159 (34.15)
105 (59.25)
>9
84 (1.96)
79 (2.00)
5 (1.00)
Smoking, n (%)
0.001 b
No
1808 (51.88)
1744 (52.92)
64 (29.21)
Yes
1,594 (48.12)
1,484 (47.08)
110 (70.79)
Drinking, n (%)
0.400 b
No
476 (11.33)
451 (11.45)
25 (8.61)
Yes
2,926 (88.67)
2,777 (88.55)
149 (91.39)
House smoker, n (%)
0.001 b
0
2,801 (82.07)
2,680 (82.73)
121 (67.59)
1–2
548 (16.18)
501 (15.68)
47 (27.22)
≥3
53 (1.75)
47 (1.59)
6 (5.19)
Hypertension, n (%)
0.010 b
No
1,662 (49.93)
1,595 (50.70)
67 (33.06)
Yes
1740 (50.07)
1,633 (49.30)
107 (66.94)
Diabetes, n (%)
0.011 b
No
2,971 (90.43)
2,833 (90.75)
138 (83.41)
Yes
431 (9.57)
395 (9.25)
36 (16.59)
Dyslipidemia, n (%)
0.504 b
No
968 (29.46)
927 (29.62)
41 (25.93)
Yes
2,434 (70.54)
2,301 (70.38)
133 (74.07)
CVD, n (%)
0.002 b
No
3,070 (92.28)
2,928 (92.58)
142 (85.65)
Yes
332 (7.72)
300 (7.42)
32 (14.35)
Asthma, n (%)
0.304 b
No
3,003 (87.39)
2,854 (87.54)
149 (83.95)
Yes
399 (12.61)
374 (12.46)
25 (16.05)
Hay fever, n (%)
0.334 b
No
3,057 (87.15)
2,899 (86.99)
158 (90.75)
Yes
345 (12.85)
329 (13.01)
16 (9.25)
Sinus infection, n (%)
0.112 b
No
2,943 (84.66)
2,803 (85.03)
140 (76.45)
Yes
459 (15.34)
425 (14.97)
34 (23.55)
Topical steroids, n (%)
0.461 b
No
3,389 (99.52)
3,215 (99.50)
174 (100.00)
Yes
13 (0.48)
13 (0.50)
0 (0.00)
Topical emollients, n (%)
0.829 b
No
3,401 (99.99)
3,227 (99.99)
174 (100.00)
Yes
1 (0.01)
1 (0.01)
0 (0.00)
Antihistamines, n (%)
0.805 b
No
3,310 (95.96)
3,142 (95.98)
168 (95.50)
Yes
92 (4.04)
86 (4.02)
6 (4.50)
Antipsychotics, n (%)
0.126 b
No
3,386 (99.38)
3,214 (99.46)
172 (97.59)
Yes
16 (0.62)
14 (0.54)
2 (2.41)
Energy, kcal, mean (±S.E)
2098.19 (±25.09)
2102.43 (±24.67)
2005.02 (±56.58)
0.066 a
Serum vitamin D, nmol/L, mean (±S.E)
61.11 (±1.22)
61.36 (±1.22)
55.57 (±2.45)
0.020 a
IgE, kU/L, mean (±S.E)
133.51 (±7.75)
133.86 (±8.23)
125.79 (±21.79)
0.750 a
Eczema, n (%)
<0.001 b
No
3,190 (92.67)
3,039 (93.06)
151 (84.06)
Yes
212 (7.33)
189 (6.94)
23 (15.94)
CDAI, Mean (±S.E)
0.23 (±0.09)
0.29 (±0.09)
−1.23 (±0.33)
<0.001 a
CDAI, n (%)
0.002 b
High
851 (26.88)
820 (27.48)
31 (13.71)
Low
2,551 (73.12)
2,408 (72.52)
143 (86.29)
Vitamin A, mcg, mean (±S.E)
606.11 (±15.10)
610.96 (±14.76)
499.73 (±44.14)
0.016 a
Vitamin C, mg, mean (±S.E)
82.85 (±2.32)
83.90 (±2.28)
59.72 (±7.41)
0.005 a
Vitamin E, mg, mean (±S.E)
7.14 (±0.15)
7.20 (±0.15)
5.87 (±0.42)
0.007 a
Magnesium, mg, mean (±S.E)
290.35 (±2.79)
292.34 (±2.70)
246.65 (±9.46)
<0.001 a
Selenium, mcg, mean (±S.E)
107.83 (±1.57)
108.47 (±1.56)
93.87 (±4.18)
0.002 a
Zinc, mg, Mean (±S.E)
12.41 (±0.31)
12.49 (±0.33)
10.61 (±0.64)
0.019 a
S.E, standard error; aWeighted t-test; bRao-Scott Chi-square test; CDAI, composite dietary antioxidant index; PIR, income-to-poverty ratio; BMI, body mass index; PA, physical activity; CVD, cardiovascular disease; IgE, immunoglobulin E.
Associations of eczema, CDAI, with depression symptoms
The associations of eczema, CDAI, with depression were illustrated in Table 2. After adjusting race, PIR, marriage, education level, sleep duration, smoking, house smoker, hypertension, diabetes, CVD, and serum vitamin D, both eczema (OR = 3.60, 95%CI: 2.39–5.40) and CDAI (OR = 1.97, 95%CI: 1.19–3.27) were associated with higher prevalence of depression symptoms. Compared to the participants with high CDAI and no eczema, those participants with low CDAI (eczema: OR = 7.30, 95%CI: 4.73–11.26; non-eczema: OR = 1.84, 95%CI: 1.06–3.19) have higher odds of depression symptoms, no matter have eczema or not. There was a significant synergistic effect of eczema and low CDAI level on depression symptoms (RERI = 4.22, 95%CI: 0.54–7.90; AP = 0.58, 95%CI: 0.20–0.95). We further explored the association of eczema with depression symptoms under different CDAI levels (Table 3). In individuals with high CDAI levels, no statistical significance relationship was found between eczema and depression symptoms (OR = 2.56, 95%CI: 0.61–10.83). When under low CDAI level, eczema was associated with increased odds of depression symptoms (OR = 3.76, 95%CI: 2.34–6.03).
The associations of eczema, CDAI with depression symptoms.
Variables
Unadjusted
Model 1
OR (95% CI)
P
OR (95% CI)
P
Eczema
No
Ref
Ref
Yes
2.54 (1.82–3.55)
<0.001
3.60 (2.39–5.40)
<0.001
CDAI
High
Ref
Ref
Low
2.38 (1.48–3.85)
<0.001
1.97 (1.19–3.27)
0.009
CDAI and Eczema
Eczema (no) and CDAI (high)
Ref
Ref
Eczema (no) and CDAI (low)
2.22 (1.31–3.75)
0.003
1.84 (1.06–3.19)
0.030
Eczema (yes) and CDAI (high)
1.51 (0.53–4.29)
0.436
2.24 (0.78–6.41)
0.134
Eczema (yes) and CDAI (low)
6.34 (3.96–10.17)
<0.001
7.30 (4.73–11.26)
<0.001
Measures
Measure (95% CI)
Measure (95% CI)
RERI
3.62 (0.66–6.57)
4.22 (0.54–7.90)
AP
0.57 (0.24–0.90)
0.58 (0.20–0.95)
OR, hazard ratio; CI, confidence intervals; Ref, reference; CDAI, composite dietary antioxidant index; RERI, relative excess risk of interaction; AP, attributable proportion; Unadjusted was crude model; Model 1 adjusting race, PIR, marriage, education, sleep duration, smoking, house smoker, hypertension, diabetes, CVD, and serum Vitamin D.
The association of eczema with depression symptoms under different CDAI level.
Variables
Unadjusted
Model 1
OR (95% CI)
P
OR (95% CI)
P
CDAI (high)
No
Ref
Ref
Yes
1.51 (0.53–4.29)
0.436
2.56 (0.61–10.83)
0.200
CDAI (low)
No
Ref
Ref
Yes
2.86 (1.84–4.45)
<0.001
3.76 (2.34–6.03)
<0.001
OR, hazard ratio; CI, confidence intervals; Ref, reference; CDAI, composite dietary antioxidant index; Unadjusted was crude model; Model 1 adjusting race, PIR, marriage, education, sleep duration, smoking, house smoker, hypertension, diabetes, CVD, and serum Vitamin D.
Subgroup analysis
The associations of eczema, CDAI, with depression were further explored in various gender, BMI, and smoking subgroups (Table 4) (Figure 2). When under low CDAI level, eczema was related to elevated odds of depression symptoms in those males (OR = 4.65, 95%CI: 1.85–11.69), females (OR = 2.91, 95%CI: 1.32–6.41), BMI <25 (OR = 3.21, 95%CI: 1.45–7.12), BMI ≥25 (OR = 3.86, 95%CI: 1.69–8.82), non-smoking (OR = 5.26, 95%CI: 2.14–12.93), and smoking (OR = 3.31, 95%CI: 2.015.47). When individuals experienced high CDAI levels, no associations were found between eczema and depression symptoms of diverse subgroups. The interaction effect of CDAI and eczema on depression was shown in Table 5.
The association of eczema with depression symptoms under different CDAI level in subgroups.
Variables
CDAI (high)
CDAI (low)
Outcome/Total
OR (95% CI)
P
Outcome/Total
OR (95% CI)
P
Gender-Male (n = 17/522)
No
n = 14/485
Ref
n = 52/1076
Ref
Yes
n = 3/37
2.69 (0.54–13.44)
0.229
n = 7/52
4.65 (1.85–11.69)
0.001
Gender-Female (n = 14/329)
No
n = 13/303
Ref
n = 72/1326
Ref
Yes
n = 1/26
5.25 (0.53–52.41)
0.158
n = 12/97
2.91 (1.32–6.41)
0.008
BMI <25 (n = 10/253)
No
n = 9/231
Ref
n = 36/718
Ref
Yes
n = 1/22
7.47 (0.47–117.65)
0.153
n = 5/53
3.21 (1.45–7.12)
0.004
BMI ≥25 (n = 21/598)
No
n = 18/557
Ref
n = 88/1684
Ref
Yes
n = 3/41
2.27 (0.63–8.19)
0.212
n = 14/96
3.86 (1.69–8.82)
0.001
Smoking-No (n = 11/446)
No
n = 10/412
Ref
n = 46/1282
Ref
Yes
n = 1/34
1.59 (0.23–11.17)
0.640
n = 7/80
5.26 (2.14–12.93)
<0.001
Smoking-Yes (n = 20/405)
No
n = 17/376
Ref
n = 78/1120
Ref
Yes
n = 3/29
3.62 (0.90–14.57)
0.070
n = 12/69
3.31 (2.01–5.47)
<0.001
Associations of eczema, CDAI, with depression symptoms in different gender, BMI, smoking subgroups.
The combined effect of CDAI and eczema on the odds of depression in subgroups.
Subgroups
Outcome/Total
Unadjusted
Model 1
OR (95% CI)
P
OR (95% CI)
P
Gender = Female
n = 98/1752
CDAI and Eczema
Eczema = No and CDAI=High
n = 13/303
Ref
Ref
Eczema = No and CDAI = Low
n = 72/1326
2.12 (0.89–5.07)
0.117
1.94 (0.74–5.05)
0.248
Eczema = Yes and CDAI=High
n = 1/26
0.94 (0.12–7.57)
0.954
1.80 (0.25–12.70)
0.588
Eczema = Yes and CDAI = Low
n = 12/97
5.37 (2.14–13.46)
0.004
6.06 (2.28–16.13)
0.023
P for trend
0.003
P for trend
0.022
RERI
3.31 (−1.42–8.05)
3.33 (−3.09–9.74)
AP
0.62 (0.09–1.15)
0.55 (−0.17–1.27)
SI
4.13 (0.31–54.29)
2.92 (0.27–32.13)
Gender = Male
n = 76/1650
CDAI and Eczema
Eczema = No and CDAI=High
n = 14/485
Ref
Ref
Eczema = No and CDAI = Low
n = 52/1076
2.30 (1.24–4.29)
0.022
1.85 (0.93–3.72)
0.157
Eczema = Yes and CDAI=High
n = 3/37
1.95 (0.72–5.24)
0.213
2.42 (0.91–6.41)
0.151
Eczema = Yes and CDAI = Low
n = 7/52
8.35 (3.48–20.02)
<0.001
9.61 (3.36–27.52)
0.013
P for trend
<0.001
P for trend
0.014
RERI
5.10 (−1.24–11.45)
6.34 (−3.11–15.79)
AP
0.61 (0.27–0.95)
0.66 (0.27–1.05)
SI
3.27 (1.03–10.34)
3.79 (0.89–16.09)
BMI < 25
n = 51/1024
CDAI and Eczema
Eczema = No and CDAI=High
n = 9/231
Ref
Ref
Eczema = No and CDAI = Low
n = 36/718
1.95 (0.80–4.76)
0.167
1.75 (0.73–4.21)
0.276
Eczema = Yes and CDAI=High
n = 1/22
0.92 (0.13–6.64)
0.934
1.36 (0.18–10.43)
0.784
Eczema = Yes and CDAI = Low
n = 5/53
5.77 (2.20–15.14)
0.004
6.41 (2.34–17.55)
0.022
P for trend
0.005
P for trend
0.023
RERI
3.90 (−1.37–9.17)
4.30 (−1.72–10.32)
AP
0.68 (0.21–1.14)
0.67 (0.18–1.16)
SI
5.48 (0.29–102.92)
4.87 (0.32–74.43)
BMI ≥ 25
n = 123/2378
CDAI and Eczema
Eczema = No and CDAI=High
n = 18/557
Ref
Ref
Eczema = No and CDAI = Low
n = 88/1684
2.36 (1.32–4.20)
0.013
1.85 (0.97–3.53)
0.135
Eczema = Yes and CDAI=High
n = 3/41
1.95 (0.76–5.01)
0.192
2.45 (0.94–6.36)
0.140
Eczema = Yes and CDAI = Low
n = 14/96
6.65 (3.21–13.75)
<0.001
7.54 (3.58–15.88)
0.006
P for trend
<0.001
P for trend
0.007
RERI
3.34 (−1.76–8.45)
4.24 (−1.94–10.42)
AP
0.50 (0.00–1.00)
0.56 (0.06–1.07)
SI
2.45 (0.64–9.45)
2.84 (0.61–13.24)
Smoking = No
n = 64/1808
CDAI and Eczema
Eczema = No and CDAI=High
n = 10/412
Ref
Ref
Eczema = No and CDAI = Low
n = 46/1282
2.10 (0.91–4.83)
0.107
1.77 (0.72–4.35)
0.268
Eczema = Yes and CDAI=High
n = 1/34
1.29 (0.16–10.34)
0.816
1.53 (0.18–12.78)
0.709
Eczema = Yes and CDAI = Low
n = 7/80
7.46 (2.40–23.17)
0.005
9.93 (2.88–34.25)
0.015
P for trend
0.003
P for trend
0.014
RERI
5.07 (−2.81–12.95)
7.63 (−3.71–18.96)
AP
0.68 (0.18–1.18)
0.77 (0.36–1.17)
SI
4.66 (0.37–58.12)
6.85 (0.36–131.66)
Smoking = Yes
n = 110/1594
CDAI and Eczema
Eczema = No and CDAI=High
n = 17/376
Ref
Ref
Eczema = No and CDAI = Low
n = 78/1120
2.36 (1.27–4.36)
0.018
1.87 (1.01–3.44)
0.103
Eczema = Yes and CDAI=High
n = 3/29
1.64 (0.66–4.03)
0.305
2.51 (1.13–5.57)
0.073
Eczema = Yes and CDAI = Low
n = 12/69
6.33 (3.31–12.10)
<0.001
6.62 (3.82–11.46)
0.001
P for trend
<0.001
P for trend
0.001
RERI
3.33 (0.17–6.49)
3.24 (−0.31–6.79)
AP
0.53 (0.22–0.84)
0.49 (0.12–0.86)
SI
2.67 (1.02–7.00)
2.37 (0.88–6.38)
OR, hazard ratio; CI, confidence intervals; Ref, reference; CDAI, composite dietary antioxidant index; Model 1 adjusting race, PIR, marriage, education, sleep duration, smoking, house smoker, hypertension, diabetes, CVD, and serum Vitamin D.
Discussion
Eczema was significantly associated with a higher prevalence of depression symptoms. Similarly, a lower level of CDAI was also associated with a higher prevalence of depression symptoms. Importantly, our study found that low CDAI levels could modulate the relationship between eczema and depression symptoms. Specifically, individuals with both eczema and low CDAI levels exhibited heightened odds of depression compared to those with higher CDAI levels. This indicated the potential protective role of dietary antioxidants in mitigating depressive symptoms associated with chronic inflammatory conditions like eczema.
Our finding was consistent with existing literature reporting the relationship between eczema and depression (7, 25, 26). Chiesa Fuxench et al. (7) reported an increased likelihood of anxiety or depression in patients with eczema, with similar results in Cheng’s research (8). There is a greater prevalence of depression, anxiety, sleep disorders, and suicidal ideation among individuals with eczema (25). Patients with eczema should be vigilant about their mental health. Anyway, our study uniquely contributes by highlighting the role of dietary antioxidants in modifying the association of CDAI with depression symptoms. Previous studies have predominantly focused on the direct impact of inflammatory processes on mental health outcomes, whereas our research underscores the importance of dietary factors in modulating this association (27). Vitamin D and E supplementations demonstrate effectiveness to some extent in improving eczema severity (28). An antioxidant diet is a protective factor against depression, and a negative relationship exists between CDAI and depression (14). Our findings added the reference to the beneficial effect of antioxidants on mental health among patients with eczema.
The mechanisms underlying the moderating of low CDAI levels on the association between eczema and depression symptoms require comprehensive investigation. Dietary antioxidants, such as vitamins C and E, carotenoids, and flavonoids, are essential in neutralizing reactive oxygen species and mitigating inflammation (13). Individuals with eczema experience heightened oxidative stress due to increased inflammation and reactive oxygen species production (1). Oxidative stress was also linked to neuronal damage and altered neurotransmitter function implicated in depression (12). Thus, higher antioxidant intake, as indicated by CDAI, may alleviate oxidative stress in eczema patients, thus reducing depressive symptoms. Secondly, dietary antioxidants possess anti-inflammatory properties that may directly benefit both eczema and depression. Eczema, characterized by skin inflammation, correlates with elevated cutaneous and serum levels of pro-inflammatory cytokines such as interleukin (IL)-4, IL-13, and IL-22 (29). It has been suggested that IL-13, by binding to dopaminergic neurons and stimulating astrocyte production of brain-derived neurotrophic factor, along with oxidative stress, could contribute to neuronal damage in the ventral tegmental and substantia nigra, potentially predisposing individuals to depression and suicidality (30, 31). By mitigating inflammation, antioxidants could potentially mitigate the systemic inflammatory response associated with eczema, potentially easing depressive symptoms. Thirdly, the gut-skin and the gut-brain axes provide additional mechanistic insights. Dietary antioxidants can influence gut microbiota composition and function, thereby modulating immune responses and the production of neuroactive compounds (32). Dysbiosis and impaired gut barrier function observed in eczema patients have been linked to both skin inflammation and depressive symptoms (33). Increased antioxidants intake may restore gut microbial balance, yielding beneficial effects on both eczema severity and mood disorders.
We found that subgroups stratified by gender, BMI, and smoking status consistently demonstrated that low levels of the CDAI intensified the association between eczema and depression symptoms. This suggests that the beneficial effects of dietary antioxidants might be widespread, impacting various demographic groups similarly. Women may experience different hormonal fluctuations that interact with antioxidant levels and their mental health outcomes, while individuals with higher BMI might have altered metabolism affecting the efficacy of antioxidants. Additionally, smoking status could play a crucial role, as smokers often have lower antioxidant levels due to lifestyle factors, potentially exacerbating both eczema and depressive symptoms.
Our findings underscore the significant role that dietary interventions can play in managing mental health outcomes for individuals with eczema. Specifically, healthcare providers should evaluate and optimize antioxidant intake in patients with eczema, as this may help mitigate the risk of depression. We recommend implementing dietary assessments that focus on patients’ current antioxidant consumption. Providers can guide patients toward a diet rich in fruits, vegetables, nuts, and whole grains-key sources of dietary antioxidants-potentially alleviating both eczema symptoms and depressive symptoms. In practical terms, healthcare providers can create structured dietary plans that incorporate these foods, alongside educational resources that highlight the benefits of antioxidant-rich diets. Collaborating with nutritionists or dietitians can further enhance these efforts, providing patients with tailored dietary strategies that align with their preferences and lifestyle constraints. Additionally, addressing the feasibility of such dietary changes is crucial; for instance, practitioners could explore local food resources, budget-friendly options, and simple recipes to make healthier eating more accessible.
The strengths of our study lie in its utilization of a large, nationally representative sample from the NHANES database, facilitating robust statistical analyses. However, several limitations should be acknowledged. Firstly, the cross-sectional design limits our ability to establish causality between CDAI, eczema, and depression. Future longitudinal studies are necessary to clarify the temporal relationships and long-term effects of dietary antioxidants on mental health outcomes. Secondly, dietary intake data were obtained according to the 24-h dietary recall interview, which may introduce potential recall bias. Further research incorporating objective measures of antioxidant status, such as biomarkers, would provide more accurate estimates of dietary antioxidant effects on eczema and depression. Lastly, residual confounding from unmeasured variables in the database cannot be discounted.
Conclusion
Our study shows that low levels of the CDAI moderate the relationship between eczema and depressive symptoms in U.S. adults. These results suggest that individuals with eczema may experience heightened depressive symptoms when CDAI levels are low. Dietary interventions aimed at increasing antioxidant intake may play a crucial role in the mental health management of individuals with eczema.
Data availability statement
Publicly available datasets were analyzed in this study. This data can be found at: NHANES (https://www.cdc.gov/nchs/nhanes/).
Ethics statement
The requirement of ethical approval was waived by Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine for the studies involving humans because Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.
The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fnut.2024.1470833/full#supplementary-material
ReferencesFrazierWBhardwajN. Atopic dermatitis: diagnosis and treatment. Am Fam Physician. (2020) 101:590–8. PMID: 32412211WeidingerSNovakN. Atopic dermatitis. Lancet. (2016) 387:1109–22. doi: 10.1016/s0140-6736(15)00149-xSilverbergJI. Atopic dermatitis in adults. Med Clin North Am. (2020) 104:157–76. doi: 10.1016/j.mcna.2019.08.009AliFVyasJFinlayAY. Counting the burden: atopic dermatitis and health-related quality of life. Acta Derm Venereol. (2020) 100:10.2340/00015555-3511. doi: 10.2340/00015555-3511SchonmannYMansfieldKEHayesJFAbuabaraKRobertsASmeethL. Atopic eczema in adulthood and risk of depression and anxiety: a population-based cohort study. J Allergy Clin Immunol Pract. (2020) 8:248–257.e16. doi: 10.1016/j.jaip.2019.08.030, PMID: 31479767MatthewmanJMansfieldKEHayesJFAdesanyaEISmithCHRobertsA. Anxiety and depression in people with eczema or psoriasis: a comparison of associations in UK biobank and linked primary care data. Clin Epidemiol. (2023) 15:891–9. doi: 10.2147/clep.S417176, PMID: 37575973Chiesa FuxenchZCBlockJKBoguniewiczMBoyleJFonacierLGelfandJM. Atopic dermatitis in America study: a cross-sectional study examining the prevalence and disease burden of atopic dermatitis in the US adult population. J Invest Dermatol. (2019) 139:583–90. doi: 10.1016/j.jid.2018.08.028, PMID: 30389491ChengBTSilverbergJI. Depression and psychological distress in us adults with atopic dermatitis. Ann Allergy Asthma Immunol. (2019) 123:179–85. doi: 10.1016/j.anai.2019.06.002, PMID: 31201863VinhNMTrangVTTDac ThuyLNTamHTXHangLTTBacPV. The anxiety and depression disorder in adults with atopic dermatitis: experience of a dermatology hospital. Dermatol Reports. (2023) 15:9524. doi: 10.4081/dr.2022.9524, PMID: 37034469FasseehANElezbawyBKorraNTanniraMDalleHAderianS. Burden of atopic dermatitis in adults and adolescents: a systematic literature review. Dermatol Ther. (2022) 12:2653–68. doi: 10.1007/s13555-022-00819-6, PMID: 36197589MinzaghiDPavelPKremslehnerCGruberFOberreiterSHagenbuchnerJ. Excessive production of hydrogen peroxide in mitochondria contributes to atopic dermatitis. J Invest Dermatol. (2023) 143:1906–1918.e8. doi: 10.1016/j.jid.2023.03.1680, PMID: 37085042BhattSNagappaANPatilCR. Role of oxidative stress in depression. Drug Discov Today. (2020) 25:1270–6. doi: 10.1016/j.drudis.2020.05.001HeHChenXDingYChenXHeX. Composite dietary antioxidant index associated with delayed biological aging: a population-based study. Aging. (2024) 16:15–27. doi: 10.18632/aging.205232, PMID: 38170244ZhaoLSunYCaoRWuXHuangTPengW. Non-linear association between composite dietary antioxidant index and depression. Front Public Health. (2022) 10:988727. doi: 10.3389/fpubh.2022.988727, PMID: 36311643XuJLiH. Association between dietary antioxidants intake and childhood eczema: results from the NHANES database. J Health Popul Nutr. (2024) 43:12. doi: 10.1186/s41043-024-00501-x, PMID: 38238860SeidelmannSBClaggettBChengSHenglinMShahASteffenLM. Dietary carbohydrate intake and mortality: a prospective cohort study and meta-analysis. Lancet Public Health. (2018) 3:e419–28. doi: 10.1016/s2468-2667(18)30135-x, PMID: 30122560ZhouTChenSMaoJFeiYYuXHanL. Composite dietary antioxidant index is negatively associated with olfactory dysfunction among adults in the United States: a cross-sectional study. Nutr Res. (2024) 124:85–93. doi: 10.1016/j.nutres.2024.02.002, PMID: 38428291KroenkeKSpitzerRLWilliamsJB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. (2001) 16:606–13. doi: 10.1046/j.1525-1497.2001.016009606.x, PMID: 11556941JorgensenDWhiteGESekikawaAGianarosP. Higher dietary inflammation is associated with increased odds of depression independent of Framingham risk score in the National Health and nutrition examination survey. Nutr Res. (2018) 54:23–32. doi: 10.1016/j.nutres.2018.03.004, PMID: 29914664XuJPZengRXZhangYZLinSSTanJWZhuHY. Systemic inflammation markers and the prevalence of hypertension: a NHANES cross-sectional study. Hypertens Res. (2023) 46:1009–19. doi: 10.1038/s41440-023-01195-0, PMID: 36707716CaiYChenMZhaiWWangC. Interaction between trouble sleeping and depression on hypertension in the NHANES 2005-2018. BMC Public Health. (2022) 22:481. doi: 10.1186/s12889-022-12942-2, PMID: 35277151WheltonPKCareyRMAronowWSCaseyDEJrCollinsKJDennison HimmelfarbC. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APHA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and Management of High Blood Pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Hypertension. (2018) 71:1269–324. doi: 10.1161/hyp.0000000000000066, PMID: 29133354WangLLiXWangZBancksMPCarnethonMRGreenlandP. Trends in prevalence of diabetes and control of risk factors in diabetes among us adults, 1999-2018. JAMA. (2021) 326:704–13. doi: 10.1001/jama.2021.9883XuFEarpJEAdamiAWeidauerLGreeneGW. The relationship of physical activity and dietary quality and diabetes prevalence in us adults: findings from NHANES 2011-2018. Nutrients. (2022) 14:3324. doi: 10.3390/nu14163324, PMID: 36014830KagePSimonJCTreudlerR. Atopic dermatitis and psychosocial comorbidities. J Dtsch Dermatol Ges. (2020) 18:93–102. doi: 10.1111/ddg.14029PatelKRImmaneniSSingamVRastogiSSilverbergJI. Association between atopic dermatitis, depression, and suicidal ideation: a systematic review and Meta-analysis. J Am Acad Dermatol. (2019) 80:402–10. doi: 10.1016/j.jaad.2018.08.063, PMID: 30365995ParisapoguAOjinnaBTChodaySKampaPRaviNSherpaML. A molecular basis approach of eczema and its link to depression and related neuropsychiatric outcomes: a review. Cureus. (2022) 14:e32639. doi: 10.7759/cureus.32639, PMID: 36660532LimJJLiuMHChewFT. Dietary interventions in atopic dermatitis: a comprehensive scoping review and analysis. Int Arch Allergy Immunol. (2024) 185:545–89. doi: 10.1159/000535903, PMID: 38442688CourtneyASuJC. The psychology of atopic dermatitis. J Clin Med. (2024) 13:1602. doi: 10.3390/jcm13061602, PMID: 38541828LuLHuXJinX. Il-4 as a potential biomarker for differentiating major depressive disorder from bipolar depression. Medicine. (2023) 102:e33439. doi: 10.1097/md.0000000000033439, PMID: 37058046VaiBMazzaMGCazzettaSCalesellaFAggioVLorenziC. Higher interleukin 13 differentiates patients with a positive history of suicide attempts in major depressive disorder. J Affect Disord Rep. (2021) 6:100254. doi: 10.1016/j.jadr.2021.100254LiXYMengLShenLJiHF. Regulation of gut microbiota by vitamin C, vitamin E and Β-carotene. Food Res Int. (2023) 169:112749. doi: 10.1016/j.foodres.2023.112749, PMID: 37254375ElhageKGKranyakAJinJQHaranKSpencerRKSmithPL. Mendelian randomization studies in atopic dermatitis: a systematic review. J Invest Dermatol. (2024) 144:1022–37. doi: 10.1016/j.jid.2023.10.016